Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

PURPOSE: Lintuzumab (HuM195), a humanized anti-CD33 antibody, targets myeloid leukemia cells and has modest single-agent activity against acute myeloid leukemia (AML). To increase the antibody’s potency without the nonspecific cytotoxicity associated with β-emitters, the α particle-emitting radionuc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rosenblat, Todd L., McDevitt, Michael R., Mulford, Deborah A., Pandit-Taskar, Neeta, Divgi, Chaitanya R., Panageas, Katherine S., Heaney, Mark L., Chanel, Suzanne, Morgenstern, Alfred, Sgouros, George, Larson, Steven M., Scheinberg, David A., Jurcic, Joseph G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2970691/
https://ncbi.nlm.nih.gov/pubmed/20858843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0382
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados